Noscapinoids: A new class of anticancer drugs demand biotechnological intervention

Medicinal Plant Biotechnology

Volumn , Issue , 2010, Pages 303-320

  Joshi, Harish C ^a   Salil, Asmita ^a   Bughani, Usha ^a   Naik, Pradeep Kumar ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955871645     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Aneja, R., Lopus, M., Zhou, J., Vangapandu, S.N., Ghaleb, A., Yao, J., Nettles, J.H., Zhou, B., Gupta, M., Panda, D., Chandra, R. and Joshi, H.C. (2006a) Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Research 66, 3782-3791.
2. Aneja, R., Vangapandu, S.N., Lopus, M., Chandra, R., Panda, D. and Joshi, H.C. (2006b) Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Molecular Pharmacology 69, 1801-1809.
3. Aneja, R., Zhou, J., Vangapandu, S.N., Zhou, B., Chandra, R. and Joshi, H.C. (2006c) Drug-resistant T-lymphoid tumours undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 107, 2486-2492.
4. Aneja, R., Dhiman, N., Idnani, J., Awasthi, A., Arora, S.K., Chandra, R. and Joshi, H.C. (2007a) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemotherapy and Pharmacology 60, 831-839.
5. Aneja, R., Ghaleb, A.M., Zhou, J., Yang, V.W. and Joshi, H.C. (2007b) p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Research 67, 3862-3870.
6. Aneja, R., Kalia, V., Ahmed, R. and Joshi, H.C. (2007c) Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection. Molecular Cancer Therapy 6, 2891-2899.
7. Aneja, R., Liu, M., Yates, C., Gao, J., Dong, X., Zhou, B., Vangapandu, S.N., Zhou, J. and Joshi, H.C. (2008) Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Research 68, 1495-1503.
8. Aneja, R., Asress, S., Dhiman, N., Awasthi, A., Rida, P.C., Arora, S.K., Zhou, J., Glass, J.D. and Joshi, H.C. (2010) Non-toxic melanoma therapy by a novel tubulin-binding agent. International Journal of Cancer 126, 256-265.
9. Battersby, A.R. and Hirst, M. (1965) Concerning the biosynthesis of narcotine. Tetrahedron Letters 11, 669-673.
10. Belotti, D., Rieppi, M., Nicoletti, M.I., Casazza, A.M., Fojo, T., Taraboletti, G. and Giavazzi R. (1996) Paclitaxel (Taxol) inhibits motility of paclitaxel resistant human ovarian carcinoma cells. Clinical Cancer Research 2, 1725-30.
11. Buschmann, T., Lin, Y., Aithmitti, N., Fuchs, S.Y., Lu, H., Resnick-Silverman, L., Manfredi, J.J., Ronai, Z. and Wu, X. (2001) Stabilization and activation of p53 by the coactivator protein TAFII31. The Journal of Biological Chemistry 276, 13852-13857.
12. Cassimeris, L., Rieder, C.L. and Salmon, E.D. (1994) Microtubule assembly and kinetochore directional instability in vertebrate monopolar spindles: implications for the mechanism of chromosome congression. Journal of Cell Science 107, 285-297.
13. Cavaletti, G., Tredici, G., Braga, M. and Tazzari, S. (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Experimental Neurology 133, 64-72.
14. Chau, N.M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., Workman, P. and Ashcroft, M. (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Research 65, 4918-4928.
15. Checchi, P.M., Nettles, J.H., Zhou, J., Snyder, J.P. and Joshi, H.C. (2003) Microtubule-interacting drugs for cancer treatment. Trends in Pharmacological Sciences 24, 361-365.
16. Dahlström, B., Mellstrand, T. and Löfdahl, C.G. and Johansson M. (1982) Pharmacokinetic properties of noscapine. European Journal of Clinical Pharmacology 22, 535-539.
17. Desai, A. and Mitchison, T.J. (1997) Microtubule polymerization dynamics. Annual Review of Cell and Developmental Biology 13, 83-117.
18. Donehower, R.C., Rowinsky, E.K., Grochow, L.B., Longnecker, S.M. and Ettinger, D.S. (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treatment Reports 71, 1171-1177.
19. Empey, D.W., Laitinen, L.A., Young, G.A., Bye, C.E. and Hughes, D.T. (1979) Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. European Journal of Clinical Pharmacology 16, 393-397.
20. Facchini, P.J. and Bird, D.A. (1998) Developmental regulation of benzylquinoline alkaloid biosynthesis in opium poppy plants and tissue cultures. In vitro Cellular and Developmental Biology-Plant 34, 69-79.
21. Frick, S., Kramell, R. and Kutchan, T.M. (2007) Metabolic engineering with a morphine biosynthetic P450 in opium poppy surpasses breeding. Metabolic Engineering 9, 169-176.
22. Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z., Buters, J.T., Fojo, T. and Poruchynsky, M.S. (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of Biological Chemistry 272, 17118-25.
23. Giannakakou, P., Gussio, R., Nogales, E., Downing, K.H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K.C. and Fojo, T. (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America 97, 2904-2909.
24. Guchelaar, H.J., ten Napel, C.H., de Vries, E.G. and Mulder, N.H. (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol. Clinical Oncology (Royal College of Radiologists (Great Britain)) 6, 40-48.
25. Haikala, V., Sothmann, A. and Marvola, M. (1986) Comparative bioavailability and pharmacokinetics of noscapine hydrogen embonate and noscapine hydrochloride. European journal of clinical pharmacology 31, 367-369.
26. Hofer, S. and Herrmann, R. (2001) Chemotherapy for malignant brain tumours of astrocytic and oligodendroglial lineage. Journal of Cancer Research and Clinical Oncology 127, 91-105.
27. Hruban, R.H., Yardley, J.H., Donehower, R.C. and Boitnott, J.K. (1989) Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63, 1944-1950.
28. Idänpään-Heikkilä, J.E. (1968) Studies on the fate of 3H-noscapine in mice and rats. Annales Medicinae Experimentalis et Biologiae Fenniae 46, 201-216.
29. Jaiswal, A.S., Aneja, R., Connors, S.K., Joshi, H.C., Multani, A.S., Pathak, S. and Narayan, S. (2009) 9-bromonoscapine-induced mitotic arrest of cigarette smoke condensate transformed breast epithelial cells. Journal of Cellular Biochemistry 106, 1146-1156.
30. Jordan, M.A. and Wilson, L. (1999) The use and action of drugs in analyzing mitosis. Methods in Cell Biology 61, 267-295
31. Joshi, H.C. and Cleveland, D.W. (1990) Diversity among tubulin subunits: toward what functional end? Cell Motility and the Cytoskeleton 16, 159-63.
32. Joshi, H.C., Palacios, M.J., McNamara, L. and Cleveland, D.W. (1992) Gamma-tubulin is a centrosomal protein required for cell cycle-dependent microtubule nucleation. Nature 356, 80-83.
33. Karlsson, M.O., Dahlström, B., Eckernäs, S.A., Johansson, M. and Alm, A.T. (1990) Pharmacokinetics of oral noscapine. European Journal of Clinical Pharmacology 39, 275-279.
34. Kavallaris, M., Tait, A.S., Walsh, B.J., He, L., Horwitz, S.B., Norris, M.D. and Haber, M. (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Research 61, 5803-5809.
35. Kavanagh, J.J. and Kudelka, A.P. (1993) Systemic therapy for gynecologic cancer. Current Opinion in Oncology 5, 891-899.
36. Ke, Y., Ye, K., Grossniklaus, H.E., Archer, D.R., Joshi, H.C. and Kapp, J.A. (2000) Noscapine inhibits tumour growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunology and Immunotherapy 49, 217-225.
37. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C. and Cavenee, W.K. (2002) The WHO classification of tumours of the nervous system. Journal of Neuropathology and Experimental Neurology 61, 215-225.
38. Krishna, R. and Mayer, L.D. (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences 11, 265-283.
39. Landen, J.W., Lang, R., McMahon, S.J., Rusan, N.M., Yvon, A.M., Adams, A.W., Sorcinelli, M.D., Campbell, R., Bonaccorsi, P., Ansel, J.C., Archer, D.R., Wadsworth, P., Armstrong, C.A. and Joshi, H.C. (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Research 62, 4109-4114.
40. Landen, J.W., Hau, V., Wang, M., Davis, T., Ciliax, B., Wainer, B.H., Van Meir, E.G., Glass, J.D., Joshi, H.C. and Archer, D.R. (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clinical Cancer Research 10, 5187-5201.
41. Lasagna, L., Owens, A.H. Jr, Shnider, B.I. and Gold, G.L. (1961) Toxicity after large doses of noscapine. Cancer Chemotherapy Reports. Part 1 15, 33-34.
42. Lipton, R.B., Apfel, S.C., Dutcher, J.P., Rosenberg, R., Kaplan, J., Berger, A., Einzig, A.I., Wiernik, P. and Schaumburg, H.H. (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39, 368-373.
43. Liscombe, D.K. and Facchini, P.J. (2008) Evolutionary and cellular webs in benzylisoquinoline alkaloid biosynthesis. Current Opinion in Biotechnology 19, 173-180.
44. Löwe, J., Li, H., Downing, K.H. and Nogales, E. (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. Journal of Molecular Biology 313, 1045-57.
45. Ludueña, R.F. (1998) Multiple forms of tubulin: different gene products and covalent modifications. International Review of Cytology 178, 207-275.
46. Mahmoudian, M. and Mojaverian, N. (2001) Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the guinea-pig. Acta Physiologica Hungarica 88, 231-237.
47. Mahmoudian, M., Mehrpour, M., Benaissa, F. and Siadatpour, Z. (2003) A preliminary report on the application of noscapine in the treatment of stroke. European Journal of Clinical Pharmacology 59, 579-581.
48. Martindale, P. (1977) In: Wade (ed.) The Extra Pharmacopoeia. Pharmaceutical Press, London, p.1250.
49. McIntosh, J.R. (1985) Spindle structure and the mechanisms of chromosome movement. Basic Life Sciences 36, 197-229.
50. Mitchison, T. and Kirschner, M. (1984) Microtubule assembly nucleated by isolated centrosomes. Nature 312, 232-237.
51. Mitchison, T., Evans, L., Schulze, E. and Kirschner, M. (1986) Sites of microtubule assembly and disassembly in the mitotic spindle. Cell 45, 515-527.
52. Newcomb, E.W., Lukyanov, Y., Schnee, T., Ali, M.A., Lan, L. and Zagzag, D. (2006) Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: a novel function for an old drug. International Journal of Oncology 28, 1121-1130.
53. Nicklas, R.B. (1997) How cells get the right chromosomes. Science 275, 632-637.
54. Nicolaou, K.C., Yang, Z., Liu, J.J., Ueno, H., Nantermet, P.G., Guy, R.K., Claiborne, C.F., Renaud, J., Couladouros, E.A. and Paulvannan, K., et al. (1994) Total synthesis of taxol. Nature 367, 630-634.
55. Oluk, E.A. (2006) Alkaloid production in tissue cultures of Papaver somniferum L. cv. Office-95. Plant Tissue Culture and Biotechnology 16(1), 1-4.
56. Perkin, W.H. and Robinson, R. (1910) Synthesis of dl-narcotine (gnoccopine). Preliminary note. Proceedings of Chemical Society 26, 48.
57. Powis, G. and Kirkpatrick, L. (2004) Hypoxia inducible factor-1alpha as a cancer drug target. Molecular Cancer Therapeutics 3, 647-654.
58. Priyadarshani, A., Katyal, A., Bhatnagar, A. and Chandra, R. (2005) 24th Annual Convention of IACR and International Symposium on 'HPV and Cervical Cancer'Poster presentations.
59. Rowinsky, E.K. and Donehower, R.C. (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacology and Therapeutics 52, 35-84.
60. Rowinsky, E.K., Cazenave, L.A. and Donehower, R.C. (1990) Taxol: a novel investigational antimicrotubule agent. Journal of the National Cancer Institute 82, 1247-1259.
61. Seetharaman, J. and Rajan, S.S. (1995) Crystal and molecular structure of noscapine. Zeftschrm fur Kristamographic 210, 111-113.
62. Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nature reviews. Cancer 3, 721-732.
63. Sharma, R.A., Harris, A.L., Dalgleish, A.G., Steward, W.P. and O'Byrne, K.J. (2001) Angiogenesis as a biomarker and target in cancer chemoprevention. The Lancet Oncology 2, 726-732.
64. Stark, G.R. (1986) Cancer chemotherapy. Progress in understanding multidrug resistance. Nature 324, 407-408.
65. Stewart, Z.A., Mays, D. and Pietenpol, J.A. (1999) Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Research 59, 3831-3837.
66. Tiveron, C., Hartley-Asp, B., Johansson, C.J. and Pacchierotti, F. (1993) Noscapine does not show aneugenic activity in mouse oocytes. Mutagenesis 8, 311-315.
67. Warolin, C. (1999) Pierre-Jean Robiquet. Revue d'histoire de la pharmacie 47, 97-110.
68. Wiernik, P.H., Schwartz, E.L., Strauman, J.J., Dutcher, J.P., Lipton, R.B. and Paietta, E. (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Research 47, 2486-2493.
69. Wilson, L. and Jordan, M.A. (1995) Microtubule dynamics: taking aim at a moving target. Chemistry and Biology 2, 569-573.
70. Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J.A., Tekmal, R.R., Petros, J. and Joshi, H.C. (1998) Opium alkaloid noscapine is an antitumour agent that arrests metaphase and induces apoptosis in dividing cells. Proceedings of the National Academy of Sciences of the United States of America 95, 1601-1606.
71. Yoshimatsu, K. and Shimomura, K. (2001) Isoquinoline alkaloid production by transformed cultures of Papaver somniferum. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 119, 52-56.
72. Zhou, J., Gupta, K., Yao, J., Ye, K., Panda, D., Giannakakou, P. and Joshi, H.C. (2002) Paclitaxelresistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. The Journal of Biological Chemistry 277, 39777-39785.
73. Zhou, J., Gupta, K., Aggarwal, S., Aneja, R., Chandra, R., Panda, D. and Joshi, H.C. (2003) Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Molecular Pharmacology 63, 799-807.
74. Zhou, J., Liu, M., Aneja, R., Chandra, R., Lage, H. and Joshi, H.C. (2006) Reversal of Pglycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Research 66, 445-452.